What Happened

Neurogene Inc. released updated Phase 1/2 data showing its NGN-401 gene therapy achieved 47 developmental milestones across 10 Rett syndrome patients, averaging 4.7 milestones per participant. Improvements showed no plateau through 30 months follow-up, with 100% of participants gaining ≥1 milestone and 70% gaining ≥2 milestones across multiple functional domains.

Who Is Affected

The trial included pediatric and adolescent/adult patients across Rett syndrome's severity spectrum. Principal investigator Dr. Bernhard Suter noted the therapy appears to restart developmental progression - an unprecedented outcome in this degenerative disorder.

Market Impact

• Validates gene therapy approach for Rett syndrome
• Creates new benchmark for functional improvements (4.7 milestones/patient)
• Registrational trial (Embolden TM) ongoing with topline data expected 2H 2027

What to Watch

Monitor Neurogene's upcoming investor webcast and FDA engagement as Phase 3 trial progresses. Long-term durability beyond 30 months remains key for commercial potential in this chronic condition.